(Reuters) – GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer arm.
The drugmaker also said that it expects pandemic-related sales in 2022 to be at similar levels to 2021, but that these would contribute less to profit due to lower margins on its antibody treatment.
($1 = 0.7378 pounds)
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; editing by Mark Potter and Jason Neely)
